11,000 Shares in Stryker Corporation $SYK Purchased by Ilmarinen Mutual Pension Insurance Co

Ilmarinen Mutual Pension Insurance Co acquired a new position in shares of Stryker Corporation (NYSE:SYK) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 11,000 shares of the medical technology company’s stock, valued at approximately $3,866,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. VanderPol Investments L.L.C. increased its position in Stryker by 1.4% during the fourth quarter. VanderPol Investments L.L.C. now owns 2,084 shares of the medical technology company’s stock worth $732,000 after purchasing an additional 28 shares during the last quarter. Lantz Financial LLC increased its position in Stryker by 5.0% during the third quarter. Lantz Financial LLC now owns 608 shares of the medical technology company’s stock worth $225,000 after purchasing an additional 29 shares during the last quarter. Stonebridge Capital Advisors LLC increased its stake in Stryker by 0.4% during the third quarter. Stonebridge Capital Advisors LLC now owns 7,198 shares of the medical technology company’s stock worth $2,661,000 after acquiring an additional 29 shares during the last quarter. Tcfg Wealth Management LLC increased its stake in Stryker by 2.7% during the third quarter. Tcfg Wealth Management LLC now owns 1,091 shares of the medical technology company’s stock worth $403,000 after acquiring an additional 29 shares during the last quarter. Finally, Mechanics Financial Corp increased its stake in Stryker by 1.2% during the fourth quarter. Mechanics Financial Corp now owns 2,458 shares of the medical technology company’s stock worth $864,000 after acquiring an additional 30 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Stryker

In related news, VP M Kathryn Fink sold 5,220 shares of Stryker stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $283.85, for a total value of $1,481,697.00. Following the completion of the transaction, the vice president owned 13,137 shares in the company, valued at approximately $3,728,937.45. The trade was a 28.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Robert S. Fletcher sold 4,544 shares of Stryker stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the completion of the transaction, the vice president owned 10,582 shares of the company’s stock, valued at $3,247,298.34. This trade represents a 30.04% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 323,264 shares of company stock worth $100,659,489. Corporate insiders own 4.60% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have issued reports on SYK. The Goldman Sachs Group reissued a “neutral” rating and set a $361.00 target price on shares of Stryker in a research note on Friday, May 1st. Weiss Ratings cut shares of Stryker from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 4th. Leerink Partners initiated coverage on shares of Stryker in a research report on Monday, April 13th. They set an “outperform” rating and a $410.00 price target for the company. Robert W. Baird set a $385.00 price target on shares of Stryker in a research report on Friday, May 1st. Finally, JPMorgan Chase & Co. dropped their price target on shares of Stryker from $445.00 to $400.00 and set an “overweight” rating for the company in a research report on Friday, May 1st. Sixteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $395.48.

Stryker Trading Down 0.6%

Shares of NYSE SYK opened at $305.73 on Friday. Stryker Corporation has a twelve month low of $281.00 and a twelve month high of $404.87. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62. The stock has a fifty day simple moving average of $321.82 and a 200-day simple moving average of $348.15. The stock has a market capitalization of $117.21 billion, a PE ratio of 35.39, a PEG ratio of 1.94 and a beta of 0.80.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). The firm had revenue of $6.02 billion during the quarter, compared to analyst estimates of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The company’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, equities analysts forecast that Stryker Corporation will post 14.98 earnings per share for the current year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be issued a $0.88 dividend. The ex-dividend date is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.2%. Stryker’s payout ratio is 40.74%.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.